Early findings point to the antitumor efficacy of the next-generation TRK inhibitor LOXO-195 in patients with NTRK fusion-positive cancers and NTRK resistance mutations acquired during treatment with first-generation agents.
Levofloxacin prophylaxis significantly reduces the risk for bacteremia among children receiving intensive chemotherapy for acute leukemia, but not among those undergoing hematopoietic stem cell transplantation, study data show.
The use of hormonal contraceptives just before and during pregnancy may significantly increase the risk for childhood non-lymphoid leukemia, Danish researchers report.
A significant overall survival benefit with the use of maintenance chemotherapy has been demonstrated by the RMS2005 trial of children who have completed standard treatment for high-risk, nonmetastatic rhabdomyosarcoma.
The addition of nelarabine and an escalating dose of methotrexate to a standard chemotherapy regimen has achieved the best ever survival outcomes for children and young adults with a new diagnosis of T-cell acute lymphoblastic leukemia who are at risk for recurrence, researchers say.
Young adult survivors of childhood cancer are at increased risk for cardiovascular disease, which develops earlier than in the general population, German study findings confirm.
The tyrosine kinase inhibitor dasatinib is effective and well tolerated as a first- or second-line therapy for children with chronic myeloid leukemia in the chronic phase, research confirms.